Novartis Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM - 8:00 PM ET, excluding holidays.
LUTATHERA has helped treat over 20,000 patients with NETs—start LUTATHERA now
LUTATHERA is a targeted treatment for patients with somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs). It can help to slow NET progression.
By starting LUTATHERA early in your treatment journey, you are taking the first steps on your path to stabilizing NETs longer.
Whether you are newly diagnosed or are currently on somatostatin analogues (SSAs), LUTATHERA early can help slow NET progression for longer.
Explore how LUTATHERA fits into your NET treatment plan